Condition
Mediastinal B-Cell Diffuse Large Cell Lymphoma
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Active Not Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05940272Not ApplicableRecruiting
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
NCT06093841Phase 2Active Not Recruiting
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT05208853Early Phase 1Unknown
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma
Showing all 3 trials